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Secondary bacterial infections often complicate viral
respiratory infections. We hypothesize that perturba-
tion of the gut microbiota during influenza A virus
(IAV) infection might favor respiratory bacterial
superinfection. Sublethal infection with influenza
transiently alters the composition and fermentative
activity of the gut microbiota in mice. These changes
are attributed in part to reduced food consumption.
Fecal transfer experiments demonstrate that the
IAV-conditioned microbiota compromises lung
defenses against pneumococcal infection. Inmecha-
nistic terms, reduced production of the predominant
short-chain fatty acid (SCFA) acetate affects the
bactericidal activity of alveolar macrophages.
Following treatment with acetate, mice colonized
with the IAV-conditioned microbiota display reduced
bacterial loads. In the context of influenza infection,
acetate supplementation reduces, in a free fatty
acid receptor 2 (FFAR2)-dependent manner, local
and systemic bacterial loads. This translates into
reduced lung pathology and improved survival rates2934 Cell Reports 30, 2934–2947, March 3, 2020 ª 2020 The Author
This is an open access article under the CC BY-NC-ND license (http://of double-infected mice. Lastly, pharmacological
activation of the SCFA receptor FFAR2 during influ-
enza reduces bacterial superinfection.INTRODUCTION
Despite thewidespread application of vaccination programs and
antiviral drug treatments, influenza A virus (IAV) infections are
responsible for significant morbidity and mortality. Influenza in-
fections can also result in sporadic and often devastating pan-
demics; the 1918 pandemic led to the death of 50 million people.
Severe bacterial infections can occur in the aftermath of IAV
infection and contribute significantly to the excess morbidity
and mortality of influenza (McCullers, 2014). Streptococcus
pneumoniae was the most commonly detected bacteria in the
1918 and 2009 influenza pandemics. Murinemodels have shown
that infection with IAV disrupts pulmonary barrier integrity and
dampens innate antibacterial immunity, thus favoring local bac-
terial outgrowth and dissemination from the lungs (Ballinger and
Standiford, 2010; McCullers, 2014; Rynda-Apple et al., 2015;
Short et al., 2014). This inability to control bacterial infection is
associated with changes in the numbers and/or functions of
innate immune cells, including alveolar macrophages, conven-
tional dendritic cells, neutrophils, and non-conventional T cellss.
creativecommons.org/licenses/by-nc-nd/4.0/).
(Barthelemy et al., 2017; Ghoneim et al., 2013; McNamee and
Harmsen, 2006; Sun and Metzger, 2014). Regarding the impor-
tance of the gut-lung axis in diseases (Budden et al., 2017; McAl-
eer and Kolls, 2018), we hypothesized that perturbation of the
gut microbiota during IAV infection might favor bacterial
superinfection.
The gastrointestinal tract hosts a complex, highly diverse mi-
crobial ecosystem. The tightly regulated interplay between the
microbiota and the host enables the establishment and persis-
tence of immune homeostasis (Blander et al., 2017; Maslowski
and Mackay, 2011; Thaiss et al., 2016). The impact of
commensal microbes on host immune responses is not limited
to the gut compartment (i.e., barrier functions and gut homeosta-
sis) but also extends to systemic compartments and distant
mucosal interfaces, such as the lungs (Budden et al., 2017;
McAleer and Kolls, 2018). The mechanism by which the gut
microbiota regulates the size and/or the functions of the
steady-state immune cell pool depends onmicrobial-associated
molecular patterns, microbial metabolites, and their interactions
with progenitor cells and mature immune cells (Arpaia et al.,
2013; Koh et al., 2016; Shapiro et al., 2014). It has recently
been shown that a healthy microbiota has a critical role in the
host’s defense against respiratory tract infections, including
IAV (Abt et al., 2012; Bradley et al., 2019; Ichinohe et al., 2011;
Moriyama and Ichinohe, 2019; Steed et al., 2017) and
S. pneumoniae (Brown et al., 2017; Clarke et al., 2010; Schuijt
et al., 2016). In the latter context, nucleotide-binding oligomeri-
zation domain (NOD)-like receptor agonists modulate the func-
tions of effector immune cells, including alveolar macrophages
and neutrophils.
Pathological situations (such as infections and chronic inflam-
matory or metabolic disorders) can modify the diversity and
composition of the gut microbiota, leading to dysbiosis (Levy
et al., 2017). Changes in intestinal bacterial communities can
influence disease outcomes even in distant organs, as demon-
strated by transfer experiments with dysbiotic microbiota. Only
a few studies have investigated the impact of an acute respira-
tory infection on the gut microbiota, and most of these involved
animal (murine) models of influenza. In this system, severe infec-
tions with H1N1 and H5N1 IAV were associated with alteration of
the gut microbiota (Bartley et al., 2017; Deriu et al., 2016; Groves
et al., 2018; Wang et al., 2014a; Yildiz et al., 2018), a finding that
seems also to apply to infections in humans (Qin et al., 2015).
This perturbation of the microbiota is associated with enhanced
susceptibility to secondary enteric infections (Deriu et al., 2016;
Yildiz et al., 2018). Influenza-associated dysbiosis has yet to be
fully characterized (e.g., metabolic output) and functionally
explored. In particular, it remains to be seen whether changes
in the composition of the gut microbiota during influenza infec-
tion affect remote (respiratory tract) bacterial infections. In the
present study, we found that sublethal infection with the H3N2
and H1N1 subtypes of influenza is associated with changes in
the composition of the gut (cecal and intestinal) microbiota and
with a drop in the production of short-chain fatty acids (SCFAs),
the end products of dietary fiber fermentation. Pair-feeding ex-
periments indicate that this phenomenon was probably due to
decreased food intake, a well-known feature of influenza (Monto
et al., 2000). Fecal transfer experiments demonstrated that thealterations in the microbiota compromised pulmonary immunity
against pneumococcal infection. We discovered that the dimin-
ished production of acetate (the predominant SCFA), by altering
the bactericidal activity of alveolar macrophages, was respon-
sible for this remote effect. Acetate supplementation during
influenza infection reinforced, in a free fatty acid receptor 2
(FFAR2)-dependent manner, lung defenses against secondary
pneumococcal infection and reduced the lethal outcome of
superinfected mice. Lastly, activation of FFAR2 by a highly spe-
cific agonist mimicked the effects of acetate and protected
against post-influenza bacterial superinfection. Our results pro-
vide new insights into the pathophysiological mechanisms that
underlie secondary bacterial infection post-influenza and might
be of value in developing appropriate therapeutic approaches
in diseases associated with dysbiosis and secondary bacterial
infections.
RESULTS
Sublethal Influenza Infection Transiently Alters the
Composition and Metabolic Output of the Gut
Microbiota
To study the impact of a sublethal influenza infection on the
composition and functionality of the gut microbiota, feces from
IAV (H3N2)-infected mice were collected, and 16S rRNA gene
profilingwasperformed.Thedeterminationof theweightedphylo-
geneticUniFrac distance (beta diversity) using unsupervised clus-
tering and principal-component analysis (PCA) clearly indicated
an intergroupdifference in the fecalmicrobiotaatday7post-infec-
tion (7 dpi), but not at 14 dpi (Figure 1A). A taxonomic analysis did
not reveal anymajor changes at the phylum level at 7 dpi, with the
exception of the Verrucomicrobia (Akkermansia) and, to a lesser
extent, the Cyanobacteria (Figure S1A; Table S1). Greater
changes were observed for lower taxonomic affiliations. Within
theBacteroidetes phylum, the relative abundanceof theBacteroi-
dales S24-7 family was reduced, while that of the Parabacteroi-
detes and Odoribacter genera was enhanced at 7 dpi (Table S1).
In the Firmicutes phylum, we observed a greater relative abun-
danceofClostridiales (unaffiliated),Ruminococcaceae, andMogi-
bacteriacecea families and theCoprococcus,Roseburia,Defluvit-
talea,Dorea,Ruminococcus, andGemmiger genera (Figure S1B).
In contrast, lower relative abundances were observed for the
Lachnospiraceae family (mainly unaffiliated Lachnospiraceae
and Clostridium genera) and the Dehalobacterium and Lactoba-
cillus (Bacilli class) genera. Lastly, within the Proteobacteria
phylum, the proportion of Alphaproteobacteria and Gammapro-
teobacteria (Escherichia genus) classes increased, while that of
Betaproteobacteria (Sutterella genus) decreased. Unsupervised
clustering andPCAof the cecal samples also revealeda clear shift
at 7 dpi relative to the controls (mock-treated mice) (Figure 1B).
Likewise, we observed variations at the phylum level and below
(Table S2). It is noteworthy that along with increased relative
abundances of Verrucomicrobia and Cyanobacteria (as was the
case in feces), we observed a dramatic drop in Actinobacteria
(Bifidobacteriaceae and Coriobacteriaceae families) in the cecal
samples.Quantitative PCRassaysdidnot reveal significant differ-
ences in the 16S rRNA gene copy number in the feces and cecal
compartment at any of the time points post-influenza,Cell Reports 30, 2934–2947, March 3, 2020 2935
Figure 1. Altered Composition and Fermenta-
tive Activity (SCFA Production) of the Gut Mi-
crobiota during IAV Infection
(A) Seven and fourteen days after IAV (H3N2) infec-
tion, fecal contents were collected for 16S rDNA
profiling. Fecal samples from each mouse were also
collected the day of infection (D0). Bacterial com-
munities were clustered using PCA of weighted
UniFrac distance matrices (beta diversity). The first
three principal coordinates (PC1, PC2, and PC3) are
plotted for each sample, and the percentage varia-
tion in the plotted principal coordinates is indicated
on the axes. Each spot represents one sample, and
each group of mice is denoted by a different color
(blue: noninfected/day 0, red: 7 dpi/day 7, green, 14
dpi/day 14). Distance between dots represents
extent of compositional difference.
(B) PCA (H3N2/cecum). Blue, noninfected (mock);
red, 7 dpi; green, 14 dpi (n = 8, one of three inde-
pendent experiments shown).
(C) Cecal concentrations of total (left panel) and in-
dividual (right panel) SCFAs in mock-treated and
IAV-infected mice (n = 21–33, five pooled experi-
ments).
(D) Cecal concentrations of total SCFAs in mock-
treated and IAV (H1N1/pdm09)-infected mice (7 dpi)
(n = 6–8, one experiment performed).
(E) Blood concentrations of total SCFAs (9–10 pooled
sera, 4 mice/pool). The repartition of individual
SCFAs in the blood is represented (mock).
Results are expressed as the mean ± SD (C–E).
Significant differences were determined using the
Kruskal-Wallis ANOVA test (C) and the Mann-Whit-
ney U test (D and E) (*p < 0.05; ***p < 0.001). See also
Figures S1–S3 and Tables S1–S3.demonstrating an overall stable gut bacterial load (Figure S1C). In
line with other studies (Wang et al., 2014a; Yildiz et al., 2018), no
IAV RNA genome was detected by quantitative PCR in the intes-
tine of IAV-infected mice (Figure S1D). This suggests that dysbio-
siswasnotdue toviral replication in this siteor topassive transport
of viralRNA into the intestinal tissue. Toexpandupon theseobser-
vations, we testedwhetherH1N1 IAV,which is the other dominant
subtype in human IAVs, alters the composition of the gut micro-
biota. Infection with H1N1 IAVs also led to clear variations in the
microbiota at 7 dpi (Figures S2 and S3; Tables S3 and S4). Similar
changes in phylogenetic specifications were observed for H1N1-
infected and H3N2-infected animals; shifts in Bacteroidales S24-
7, Lachnospiraceae, Ruminococcus, Lactobacillus, Sutterella,
andAkkermansia (relative tocontrols)wereobserved forboth virus
subtypes.Collectively, sublethal influenza (H3N2andH1N1) infec-
tion leads to transient gut dysbiosis.
Since changes in the composition of the gut microbiota can
alter its functionality (e.g., metabolic activity), we quantified the
production of SCFAs, major metabolites of the gut microbiota,
during the course of influenza infection. SCFAs are generated2936 Cell Reports 30, 2934–2947, March 3, 2020by bacterial fermentation of colonic dietary
fibers, reaching high concentrations in the
gut lumen under physiological conditions
(Koh et al., 2016). As shown in Figure 1C
(left panel), the total SCFA concentrationin the cecum 7 days after H3N2 infection was lower relative to
noninfected mice. The concentrations of acetate (the predomi-
nant SCFA), propionate, and butyrate were all lower (Figure 1C,
right panel). At 14 dpi, the cecal SCFA concentrations returned to
basal levels. A significantly reduced concentration of SCFAswas
also observed at 7 dpi inmice infectedwith H1N1 IAV (Figure 1D).
It is known that SCFAs produced in the gut can pass into the sys-
temic circulation and then exert remote biological effects (partic-
ularly acetate and, to a lesser extent, propionate and butyrate)
(Cait et al., 2018; Macia et al., 2015; Trompette et al., 2014). As
seen in Figure 1E, influenza infection resulted in a lowered con-
centration of SCFAs in the blood at 7 dpi. In agreement with other
studies (Cait et al., 2018; Macia et al., 2015; Marin˜o et al., 2017;
Trompette et al., 2014), acetate was the predominant SCFA
found in the blood. These data show that influenza infection
alters the metabolic (fermentative) output of the gut microbiota
at 7 dpi and that it affects local (gut) and systemic (blood)
concentration of SCFAs, an emerging group of dietary derived
metabolites endowed with immune regulatory functions (Tan
et al., 2014).
Figure 2. Enhanced Susceptibility to Respiratory Bacterial Infection in Mice Colonized with the IAV-Experienced Microbiota
(A) The experimental design for microbiota adoptive transfer is shown. 1 day after the second colonization, mice were challenged with S. pneumoniae (1 3 106
colony-forming units [CFUs]). Non-recolonized ABX-treated mice were infected 3 days after ABX cessation.
(B) The number of viable bacteria in the lung was determined 30 h after the bacterial challenge. The solid lines correspond to themedian values (n = 10, pool of two
independent experiments).
(C and D) The same procedure was performed, but this time, ABX-treated mice were recolonized with the cecal microbiota collected from mock-treated mice or
IAV-infected mice (H3N2 or H1N1, C and D, respectively). n = 19–21 (C) and n = 14 (D) (pool of three or two independent experiments).
Significant differences were determined using the Kruskal-Wallis ANOVA test (B) and the Mann-Whitney U test (C and D) (*p < 0.05; **p < 0.01).The IAV-Experienced Microbiota Confers Susceptibility
to Respiratory Bacterial Infection
Through the continuous release of soluble factors, the gut micro-
biota can act at distance to modulate pulmonary immunity (Abt
et al., 2012; Bradley et al., 2019; Brown et al., 2017; Clarke
et al., 2010; Ichinohe et al., 2011; Schuijt et al., 2016; Steed
et al., 2017). We thus investigated the potential consequences
of IAV-induced gut dysbiosis on pulmonary antibacterial
defenses. To this end, we performed microbiota transfer exper-
iments (experimental protocol in Figure 2A). Using this approach,
recent reports have demonstrated that a healthy gut microbiota
can enhance resistance to pulmonary pneumococcal infection
(serotype 3) (Brown et al., 2017; Clarke et al., 2010; Schuijt
et al., 2016). To investigate this putative effect in our experi-
mental model, mice were treated with broad-spectrum antibi-
otics (ABX), to disrupt the residual microbiota, and were then
intranasally challenged with S. pneumoniae serotype 1, a major
serotype in humans. Relative to conventional (microbiota profi-
cient) mice, ABX-treated mice displayed a greater bacterialload in their lungs, and oral administration of gut microbiota
collected from healthy mice restored bacterial clearance (Fig-
ure 2B). These data confirm that a transient arrest of micro-
biota-derived input signals (here due to ABX treatment) can alter
the early pulmonary defenses against bacterial infection.
We next determined whether a loss of input signals due to prior
influenza infection could compromise antibacterial pulmonary de-
fense. To this end, the gut microbiota collected from IAV-infected
mice was transplanted into ABX-treated mice. Strikingly, mice
colonized with the IAV (H3N2)-experienced microbiota had a
significantly greater bacterial count in the lungs than mice colo-
nizedwith themock (control) gutmicrobiota (Figure 2C, left panel).
The dysbiotic IAV-conditionedmicrobiota also enhancedbacterial
dissemination from the lungs, as revealed by the higher number of
viable bacteria in the spleen (Figure 2C, right panel). To investigate
whether this effect was strain specific, the same procedure was
repeated using gut microbiota collected from H1N1-infected
mice. This also led to enhanced susceptibility to pulmonary pneu-
mococcal infection (Figure 2D). This finding indicates that theCell Reports 30, 2934–2947, March 3, 2020 2937
Figure 3. Reduced SCFA Production by the IAV-Experienced Microbiota and Effect of Acetate (Ace) Supplementation on Host Defense
against Pneumococcal Infection
(A) Total cecal SCFA concentration in conventional mice, ABX-treated mice, and ABX-treated recolonized mice (n = 4–7, one of two independent experiments
shown).
(B) Total (left panel) and individual (right panel) cecal SCFA concentration in mice recolonized with the microbiota collected from mock-treated mice or IAV
(H3N2)-infected mice (7 dpi). n = 8 (one of two independent experiments shown).
(C) Recolonized mice (IAV-conditioned microbiota, 7 dpi) were infected with S. pneumoniae (1 3 106 CFUs). Mice were treated with Ace (200 mM in drinking
water) or vehicle (Vh) 5 days before the pneumococcal challenge (n = 15–20, pool of three independent experiments).
(D) S. pneumoniae colonies at exponential growth were added to culture medium in the absence or presence of grading concentrations of Ace or, as a positive
control, 1 U/mL penicillin and 1 mg/mL streptomycin. The optical density (O.D.). was measured over time, as stated in the figure.
Results are expressed as themean ±SD (A and B). Significant differenceswere determined using the Kruskal-Wallis ANOVA test (A) and theMann-Whitney U test
(B and C) (*p < 0.05; **p < 0.01).altered pulmonary response transferred by the IAV-conditioned
microbiota is a general consequence of influenza infection,
regardless of the viral subtype. Hence, disturbance of the micro-
bial equilibrium in the gut during influenza infection enhances sus-
ceptibility to respiratory bacterial infections.
Reduced Acetate Production by the IAV-Experienced
Microbiota Is Responsible for Enhanced Susceptibility
to Respiratory Bacterial Infections
We next investigated whether the greater susceptibility of mice
colonized with the dysbiotic IAV-conditioned microbiota associ-
ates with lower SCFA production. As expected, the cecal SCFA
concentration was much lower in ABX-treated mice than in con-
ventional animals, and colonization with a healthy microbiota
partially restored the SCFA content (Figure 3A). Interestingly, rela-
tive tomicecolonizedwith themock-conditionedmicrobiota,mice
colonized with the IAV-conditioned microbiota had significantly
lower concentration of SCFAs (Figure 3B, left panel). In particular,
the concentration of acetate and propionate was reduced (Fig-
ure 3B, right panel). It is noteworthy that at this time point, the con-
centration of butyrate remained at basal level. Together, altered
respiratory defenses of colonized mice (IAV-conditioned micro-
biota) associate with reduced SCFA production.2938 Cell Reports 30, 2934–2947, March 3, 2020We then addressed the hypothesis that the drop of SCFAs
may affect the pulmonary response. To this end, we looked at
whether SCFA supplementation of IAV-conditioned microbiota-
transplanted mice could reverse the dysfunctional pulmonary
response against S. pneumoniae. We focused on acetate, as it
represents the predominant SCFA found systematically (Cait
et al., 2018; Macia et al., 2015; Trompette et al., 2014) and Fig-
ure 1E). Remarkably, acetate supplementation (drinking water)
diminished bacterial count in the lungs and reduced systemic
spread of bacteria from the lungs (Figure 3C). SCFAs can exert
bactericidal and/or bacteriostatic functions (Coussens et al.,
2015; Wang et al., 2014b). As shown in Figure 3D, acetate had
no direct effect on S. pneumoniae outgrowth in vitro. Together,
the fermentation product acetate can restore the defective anti-
bacterial pulmonary response conferred by the dysbiotic IAV-
conditioned microbiota.
Restricted Food Intake (Mimicking Influenza Disease)
Alters the Gut Microbiota and the Pulmonary Defense
against Bacterial Infection
Rapid decreased food intake can alter the composition and the
metabolic activity of the gut microbiota (Li et al., 2017). We hy-
pothesized that one of the most influential factors that might
Figure 4. Altered Gut Microbiota and Pulmo-
nary Defense against Pneumococcal Infection
in Pair-Fed Mice
(A) Kinetic measurement of body weight loss of pair-
fed mice and IAV-infected mice (n = 8, one out of
three experiments performed).
(B) Analysis of the gut microbiota (feces) in pair-fed
mice. Bacterial diversity following food restriction
was determined by PCA andwas compared to that in
IAV-infected mice (H3N2, 7 dpi).
(C) Concentrations of cecal total SCFAs in nourished
mice, pair-fed mice, and IAV-infected (7 dpi) mice
(n = 14, pool of two independent experiments).
(D) Nourished and pair-fed mice were infected with
S. pneumoniae (1 3 106 CFUs).
(E) ABX-treated mice were recolonized with the mi-
crobiota collected from nourished mice or from pair-
fed mice. Recolonized mice were infected 3 days
after the first recolonization (1 3 106 CFUs).
(F) Mice recolonized with the dysbiotic (pair-fed-
conditioned) microbiota were treated or not with Ace
as described in Figure 3C.
n = 13–16 (D–F) (two pooled experiments). Results
are expressed as the mean ± SD (A–C). Significant
differences were determined using the Kruskal-
Wallis ANOVA test (C) and the Mann-Whitney U test
(D–F) (*p < 0.05; **p < 0.01; ***p < 0.001). See also
Figure S4 and Table S5.result in alterations of the gut microbiota during influenza infec-
tion is decreased food intake (due to anorexia). In our sublethal
infection model, influenza infection is associated with decreased
food intake (and body weight loss) from days 4 to 11, with a peak
at day 7 (reaching85%) (Figure S4A, left panel). In order to test
whether gut dysbiosis during influenza infection may be due to
reduced food consumption, we designed a pair-feeding experi-
ment. We restricted the food intake of noninfected mice, with
reductions of 10%, 35%, and 85% on days 4, 5, and 6, respec-
tively (based on measurement of food consumption by infected
animals; Figure S4A, right panel) in order to have body weight
loss similar to IAV-infectedmice. These pair-fedmicewere sacri-
ficed at day 7. As depicted in Figure 4A, pair-fed mice lost weight
(relative to normally fed mice) in much the same way as IAV-in-
fected animals and had lost 15% of their initial weight at the
time of the sacrifice. An analysis of the beta diversity clearly
showed that the bacterial population from pair-fed mice differed
from that of nourished mice and tended to cluster with the
population from the IAV-infected mice at 7 dpi (Figure 4B; data
not shown). Although the diet-imposed rapid weight loss did
not fully recapitulate the phenotype of influenza infection, a
taxonomic analysis revealed several common shifts in the diver-
sity and abundance of taxa (e.g., Parabacteroides, Lachnospira-
ceae, Lactobacillus, Alphaproteobacteria, and Akkermansia)
for pair-fed mice and IAV-infected mice (Figures S4B and S4C;CellTable S5). Relative to nourished mice,
pair-fed mice displayed lower cecal
concentration of SCFAs (Figures 4C and
S4D).
To investigate the effect of food restric-
tion on the host’s pulmonary defenses,pair-fed mice were infected with S. pneumoniae. As shown in
Figure 4D, the bacterial counts in the lungs and spleen were
higher in pair-fedmice than in control mice. To elucidate whether
the gut microbiota is causal for this enhanced susceptibility, we
performed microbiota transplantation experiments. The experi-
ments indicated that this enhanced susceptibility was at least
in part due to altered gut microbiota (Figure 4E). We next tested
our presumption that reduced acetate production in pair-fed
animals (due to dietary fiber deprivation) could enhance suscep-
tibility to pneumococcal infection. Indeed, acetate supplementa-
tion significantly reduced the bacterial load in mice that received
the pair-fed-conditioned (dysbiotic) microbiota (Figure 4F).
Together, food restriction mimicking influenza disease alters
the composition and metabolic activity of the gut microbiota
and increases susceptibility to respiratory bacterial infections.
These results support the notion that reduced food consumption
during influenza infection contributes to dysbiosis and altered
pulmonary defenses against bacterial infections.
The IAV-Conditioned Microbiota Impairs the
Bactericidal Activity of Alveolar Macrophages, an Effect
Restored by Acetate Supplementation
We next sought to gain insights into the mechanisms through
which the IAV-conditioned microbiota compromises the host’s
pulmonary defenses. Alveolar macrophages, conventionalReports 30, 2934–2947, March 3, 2020 2939
dendritic cells, neutrophils, invariant natural killer T cells (iNKT)
cells, and gd T cells play a (direct or indirect) role in the early clear-
ance of pneumococci (Cao et al., 2014; Nakamatsu et al., 2007;
van der Poll and Opal, 2009; Paget and Trottein, 2019). Flow cy-
tometry analysis indicated that colonizedmice (mock-conditioned
microbiota and IAV-conditioned microbiota) displayed an iden-
tical number of these cells in the lungs (Figures 5A, S5A, and
S5B). We and others have shown that interferon-g (IFN-g) and
interleukin-17A (IL-17A) production by iNKT cells and gd T cells,
respectively, contributes to the control of pneumococci outgrowth
(Barthelemy et al., 2017; Cao et al., 2014; Hassane et al., 2017).
Intracellular flow cytometry indicated a similar number of IFN-g-
expressing iNKT cells and IL-17A-expressing gd T cells upon
S. pneumoniae challenge in the twogroupsof colonizedmice (Fig-
ure 5B). Phagocytosis is an important early event in the control of
S. pneumoniae. To evaluate this, colonized mice were infected
with EGFP-expressing S. pneumoniae (serotype 1), and 4 h later,
cells were collected from the bronchoalveolar lavage (BAL) fluids.
At this time point, alveolar macrophages represented by far the
main cell population in the BAL fluids (>95%), and their numbers
were similar in the two groups (data not shown). Confocal micro-
scopy did not reveal any significant differences between the
groupsof animalswith regard to (1) the frequency ofmacrophages
having internalized S. pneumoniae and (2) the average number of
internalized bacteria per macrophage (Figures 5C and 5D). Quan-
titative real-time PCR (16S S. pneumoniae) assay on sorted alve-
olar macrophages confirmed this finding (Figure 5E). We next
turned to investigate potential alteration of the bactericidal activity
of alveolar macrophages. To evaluate this, the killing activity of
alveolar macrophages was measured. Compared to the control
group, alveolar macrophages collected from IAV-conditioned mi-
crobiota-colonized mice displayed an altered capacity to kill
pneumococci (Figure 5F). Indeed, in this animal group, an
enhanced number of viable internalized bacteria were counted af-
ter macrophage lysis and bacterial culture. Hence, alveolar mac-
rophages (IAV-conditioned microbiota) kill pneumococci less
effectively.
We then looked at whether acetate treatment of colonized
mice (IAV-conditioned microbiota) could affect pulmonary cell
number and/or activation. Relative to controls, acetate treatment
did not significantly modify the frequency/number of macro-
phages, conventional dendritic cells, neutrophils, and unconven-
tional T cells or the activation threshold of the later (Figures 5A,
5B, and S5B). We then investigated whether acetate treatment
could reverse the altered effector functions of alveolar macro-
phages. Acetate treatment had no impact on phagocytosis ac-
tivity of alveolar macrophages but enhanced their killing activity
(Figures 5D–5F). To further demonstrate the role of alveolar mac-
rophages in acetate-induced pulmonary defense, colonized
mice were treated with clodronate-loaded liposomes. Macro-
phage depletion (Figure S5C) abrogated the protective effect
of acetate (Figure 5G). To investigate whether acetate directly
targets macrophages, killing assays were performed in vitro.
Pretreatment of macrophages with acetate enhanced the killing
of pneumococci (Figure 5H). Collectively, the dysbiotic IAV-
conditioned microbiota lowers pneumococci clearance through
impairment of alveolar macrophage functions, an effect restored
by acetate supplementation.2940 Cell Reports 30, 2934–2947, March 3, 2020Supplementation of Acetate during Influenza Protects
against Lethal Bacterial Superinfection
We then investigated the potential contribution of altered SCFA
production during IAV infection on secondary bacterial infection.
To this end, IAV-infected mice were treated with acetate and
secondarily infected with S. pneumoniae at day 7, the peak of
susceptibility. Remarkably, acetate supplementation lowered
the bacterial load in the lungs and resulted in reduced systemic
spread of bacteria from the lungs in double-infected mice (Fig-
ure 6A). The combined use of acetate, propionate and butyrate
did not further enhance resistance, relative to acetate alone (Fig-
ure S6A). Of note, the protective effect triggered by acetate did
not associate with major changes in the composition of the gut
microbiota (Figures 6B, S6B, and S6C). To determine the effect
of acetate on pulmonary damage, we evaluated and scored
lung samples histopathologically. Compared to the control
group, acetate-treated mice had less marked pneumonia,
including perivascular inflammatory infiltrates (Figure 6C). We
then determined whether the positive effect of acetate on bacte-
rial loads and lung pathology extended to ameliorated morbidity
and mortality outcomes. While acetate treatment had no effect
on weight loss due to IAV infection, it favored weight regain after
secondary pneumococcal infection (Figure S7A). Most notably,
supplementation of acetate during the course of IAV infection
effectively and significantly improved survival of double-infected
mice (50% survival rate; Figure 6D).
We next assessed mechanisms through which acetate was
able to ameliorate disease outcomes of superinfected mice. Vi-
rus-induced alteration of epithelial barrier functions contributes
to bacterial superinfection (Barthelemy et al., 2018; McCullers,
2014; Rynda-Apple et al., 2015). Acetate treatment did not affect
viral load in lungs and had no effect on the expression of genes
associated with pulmonary barrier functions, the expression of
whichwas strongly altered during influenza (Figure 6E). Likewise,
acetate failed to affect the expression of IFN-inducible genes
and antiviral mediators (Figure S7B). Hence, acetate does not
act on viral replication and associated epithelial dysfunction.
We then reasoned that the beneficial effect of acetate might
rely on antibacterial functions of immune cells. Compared to
controls, acetate treatment did not modify the number of
macrophages, conventional dendritic cells, neutrophils, IFN-g-
expressing iNKT cells, and IL-17A-expressing gd T cells (Figures
S7C and S7D). Of interest, macrophage depletion by clodronate-
liposome inoculation abrogated the beneficial effect of acetate
(Figure 6F). Taken as a whole, low acetate production during
influenza infection influences susceptibility to secondary bacte-
rial infection, and supplementation of acetate (in part through
macrophages) is sufficient to improve disease outcomes.
Exogenous Administration of a Synthetic FFAR2 Agonist
Protects against Post-influenza Secondary Bacterial
Infection
Acetate can act through the G-protein-coupled receptors FFAR2
(formerly GPR43) and, to a lesser extent, FFAR3 (formerly GPR41)
(Milligan et al., 2017). Relative to FFAR2-competent mice, acetate
failed to significantly lower bacterial loads in superinfected
Ffar2/ mice (Figure 7A). Of note, no significant difference was
noticed in terms of viral (not shown) and bacterial loads between
Figure 5. Altered Bactericidal Activity of AlveolarMacro-
phages in Mice Recolonized with the Dysbiotic IAV Mi-
crobiota
(A) Lung cells from recolonized mice were analyzed by flow cy-
tometry. The mean number ± SD of alveolar macrophages and
neutrophils are depicted.
(B) Recolonized mice were infected with S. pneumoniae (13 106
CFUs), and 16 h later, the mean number ± SD of iNKT cells
positive for IFN-g and gd T cells positive for IL-17A were deter-
mined. n = 8 (A and B) (two pooled experiments).
(C) Colonized mice were infected with EGFP-expressing
S. pneumoniae (1 3 106 CFUs). 4 h later, binding and internali-
zation of bacteria (green) was assessed by confocal microscopy.
Representative images are shown. Nuclei (blue) were visualized
by staining with DAPI. The central image is a maximum intensity
projection of the image stack (scale bars, 10 mm; insert magni-
fication, 23). Top and right: orthogonal view for the axis yz and
xz.
(D) The frequency of macrophages having internalized
S. pneumoniae and the average number of internalized bacteria
per macrophage are depicted (n = 6; one representative exper-
iment out of two).
(E) Quantification of S. pneumoniae in sorted alveolar macro-
phages (4 h after infection) by quantitative PCR. Data were
normalized against expression of the gapdh gene, and data are
expressed as DCt. One representative experiment out of two is
depicted.
(F) Alveolarmacrophageswere collected from colonizedmice 4 h
after S. pneumoniae infection. After extensive washing, cells
were lysed and plated on blood agar plates. The number of viable
bacteria is expressed per 1 3 105 cells (n = 7–14, two pooled
experiments).
(G) Ace-treated colonized mice (ABX/IAV) were treated with
clodronate-loaded liposomes or empty liposomes 16 h before
S. pneumoniae challenge (intranasal route) (n = 11–12, two
pooled experiments).
(H) Macrophages were pretreated with Ace (10 mM) for 1 h and
next exposed to opsonized S. pneumoniae. The number of viable
bacteria was assessed 2 h post-bacterial exposure by counting
CFUs from cellular lysate. Data are representative of two inde-
pendent experiments (n = 6).
Results are expressed as themean ±SD (A, B, and D). Significant
differences were determined using the Kruskal-Wallis ANOVA
test (A, B, and D–F) and the Mann-Whitney U test (G and H) (*p <
0.05; **p < 0.01; ***p < 0.001). See also Figure S5.
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Figure 6. Effect of Ace Supplementation in Mice Doubly Infected with IAV and S. pneumoniae
IAV-infected mice were treated with Ace (200 mM in drinking water) or Vh at 2 dpi, 5 days before the pneumococcal challenge (1 3 103 CFUs).
(A) The number of bacteria was determined 30 h after the S. pneumoniae challenge (n = 8–9, one representative experiment out of four is shown).
(B) PCA was performed on samples (cecum) collected from uninfected mice treated (bright blue) or not (dark blue) with Ace for 5 days and from mice infected
7 days earlier with H1N1 and treated (pink) or not (red) with Ace at 2 dpi (n = 4–5).
(C) Histological analysis of lung sections. Blinded sections were scored for levels of pneumonia (left; sum of different parameters), including perivascular in-
flammatory infiltrates (right) (n = 4 mice/group).
(D) The survival of superinfected animals was monitored (n = 14, two pooled experiments).
(E) Left: IAV M1 mRNA levels were measured in the whole lungs by quantitative RT-PCR. Data are expressed as Ct values. The dashed line represents the
detection threshold. Right: mRNA copy numbers of genes were quantified by RT-PCR. Data are expressed as fold increase over average gene expression in
mock-treated animals. One representative experiment out of two is shown (n = 5). Cdh5, VE-cadherin; Ocln, occluding).
(F) Ace-treated IAV-infectedmice were depleted (clodronate containing liposomes), or not (empty liposomes), in alveolar macrophages before the pneumococcal
challenge (n = 7–8, one experiment performed).
Results are expressed as the mean ± SD (C and E). Significant differences were determined using the Mann-Whitney U test (A and F) or ANOVA followed by the
Holm-Sidak test (C). In (D), survival of mice was compared using Kaplan-Meier analysis and the log-rank test (*p < 0.05; **p < 0.01). See also Figures S6 and S7.vehicle-treated wild-type and Ffar2/ mice. FFAR2 is amenable
to pharmacological manipulation in vivo (Milligan et al., 2017). Of
note, alveolar macrophages expressed transcripts for ffar2, while
ffar3mRNA expression was much lower (16-fold less expression)
(Figure 7B). To investigate the potential consequences of local
FFAR2 activation on post-influenza bacterial superinfection,
mice were treated with TUG-1375 (a selective FFAR2 agonist)
by intra-nasal administration. Pharmacological FFAR2 activation,2942 Cell Reports 30, 2934–2947, March 3, 2020just before pneumococcal challenge, led to a significant reduction
of lung bacterial burden and dissemination to blood (Figure 7C). In
contrast, the selective FFAR3 agonist AR420626 failed to confer
any protection (Figure 7D). Hence, the FFAR2 agonist TUG-1375
provided the same benefit as acetate in the treatment of post-
influenza bacterial superinfection. This latter finding opens up
important new possibilities for pharmacological management of
post-influenza bacterial superinfection.
Figure 7. Effect of FFAR2 Agonist Treatment
on Bacterial Superinfection Post-influenza
(A) Wild-type (WT) mice and Ffar2/ mice (litter-
mates) were treated with Ace as in Figure 6A (n = 5–
7, one representative experiment out of two is
shown).
(B) Ffar2 and Ffar3 transcript levels were assessed
by quantitative RT-PCR on enriched alveolar mac-
rophages (two independent experiments).
(C and D) IAV-infected mice were treated with the
selective FFAR2 agonist TUG-1375 (C) or with the
selective FFAR3 agonist AR420626 (D) (1 mM in
50 mL, intranasal [i.n.] route) or Vh 16 h before the
pneumococcal challenge. n = 13–14 (C) (two pooled
experiments) and n = 6–8 (D) (one representative
experiment out of two).
Results are expressed as the mean ± SD. Signifi-
cant differences were determined using the Krus-
kal-Wallis ANOVA test (A) and the Mann-Whitney U
test (B–D) (*p < 0.05; **p < 0.01).DISCUSSION
A large body of research indicates that alterations in the gut mi-
crobiota have a role in the pathogenesis of various chronic dis-
eases. The present study sought to analyze the impact of an
acute respiratory infection on the gut microbiota and study the
consequences of any functional perturbations on disease out-
comes. Our results showed that influenza infection alters the
composition and functionality of the gut microbiota and that
these changes account for enhanced susceptibility to secondary
pulmonary bacterial infections. Our study also highlighted the
importance of gut-microbiota-derived SCFAs (acetate) on the
host’s pulmonary defenses against bacterial (super)infections.
Recent reports have indicated that influenza infections in hu-
mans (H7N9) and in murine models (H1N1 and H5N1) alter the
composition of the gut microbiota (Bartley et al., 2017; Deriu
et al., 2016; Groves et al., 2018; Qin et al., 2015; Wang et al.,
2014a; Yildiz et al., 2018). Our data confirm and extend theseCell Rfindings (both H3N2 and H1N1 subtypes).
In our settings (sublethal inocula), influenza
infection altered the relative abundances
of microbial taxa at 7 dpi in both the cecum
and the colon, resulting in significant
changes in beta diversity. In contrast to
chronic diseases in which phylogenic di-
versity falls markedly, we observed
marked changes for lower taxonomic affil-
iations during influenza. At 7 dpi, we
observed the emergence of several bacte-
rial genera that were absent or almost
absent in noninfected animals, notably
Escherichia (Proteobacteria) and the
mucus-degrading bacterium Akkermansia
(Verrucomicrobia). Importantly, the alter-
ation of the gut microbiota’s composition
at 7 dpi was associatedwith a concomitant
drop in the intestinal concentration ofSCFAs, an effect that might have been due to lower abundances
of SCFA-producing bacteria. Among potential candidates (with
low numbers at 7 dpi; see Tables S2 and S4) are Lachnospira-
ceae (Firmicutes), Lactobacillaceae (lactobacillus genus), and
Bifidobacteriaceae (Actinobacteria) families, which are notable
for containing many species capable of fermenting complex car-
bohydrates into SCFAs. In line with the known resilience of the
gut community to short-term perturbations, the microbiota
changes during influenza infection were transient with an overall
return to a baseline profile at 14 dpi. At this time point, mice
recover from weight loss and display higher resistance to sec-
ondary bacterial infections (Barthelemy et al., 2016; data not
shown).
Food intake and diet composition can rapidly shape the struc-
ture and function of the gut microbiota (David et al., 2014; Desai
et al., 2016; Maslowski et al., 2009). Moreover, previous studies
have revealed that fasting and feeding rhythms significantly alter
the gut microbiota (Thaiss et al., 2016). Loss of appetite is aeports 30, 2934–2947, March 3, 2020 2943
feature of influenza (Monto et al., 2000). In view of our present re-
sults, we suggest that decreased food intake during influenza
infection, and thus reduced amounts of ingested complex carbo-
hydrates, from 4 dpi onward is at least partly responsible for
perturbation of the microbiota. Indeed, food-restricted mice
(mimicking the situation in influenza) displayed several micro-
biota changes also found in IAV-infected mice, including, for
instance, Lachnospiraceae and Lactobacillus (reduced) and Al-
phaproteobacteria and Akkermansia (augmented). As also
observed during influenza infection, food restriction was associ-
ated with a drop in SCFA production. Reduced availability of di-
etary fibers and complex carbohydrates due to food restriction
may influence competition between gut commensals at the
expense of SCFA producers and to the benefit of bacteria using
host mucins as an energy source (Desai et al., 2016). Acute
starvation inmice decreases host resistance to respiratory pneu-
mococcal infection (Mancuso et al., 2006). In our model of
pair-feeding that mimicked the situation encountered during
IAV infection, we observed increased susceptibility to
S. pneumoniae. Fecal transfer experiments indicated that pertur-
bation of the gut microbiota of pair-fed mice has an impact on
pulmonary defenses, an effect reversed by supplementation of
the fermentation product acetate. This raises important ques-
tions about the consequences of severely reduced food (fiber)
intake (e.g., due to pathologies, stresses, or voluntary fasting)
on the delivery of immune regulatory signals by the gut micro-
biota, a topic that warrants further investigation. Although we
cannot completely rule out the existence of other mechanisms,
including systemic or local inflammatory factors (such as IFNs)
(Deriu et al., 2016; Wang et al., 2014a), our data argue strongly
for a critical role of altered nutritional status (due to anorexia) in
dysregulation of the microbiota’s composition and function dur-
ing influenza infection. The reduced consumption of fruit and
vegetables rich in fibers (an indirect source of SCFAs) in western
countries, and the associated reduced richness of the gut micro-
biota, is likely to amplify this phenomenon.
Recent data indicate that dysbiosis in the upper respiratory
compartment contributes to post-influenza secondary bacterial
infections (Planet et al., 2016). The present study is the first to
have addressed the question of whether alterations in the gut mi-
crobiota might predispose to secondary bacterial infections of
the lung. A continuous input from complex microbiota is neces-
sary to maintain the (pulmonary) innate immune system. We
hypothesized that a loss of input from gut-microbiota-derived
signals during IAV infection may have negative consequences
on pulmonary defenses against bacterial infection. Fecal transfer
experiments demonstrated that (metabolic) gut microbiota
changes during influenza infection have an impact on respiratory
bacterial infection (enhanced local outgrowth and dissemination
from the lungs). Our data are in line with recent reports demon-
strating that a healthy gut microbiota favors pulmonary host
defense by improving the antibacterial activities of alveolar mac-
rophages (Brown et al., 2017; Clarke, 2014; Lankelma et al.,
2017; Schuijt et al., 2016). These cells are particularly relevant
in bacterial infections, since loss of their functions (e.g., during
influenza) favors the replication of opportunistic pathogenic bac-
teria, including S. pneumoniae (Ghoneim et al., 2013; Sun and
Metzger, 2014). Of interest, while supplementation of NOD-like2944 Cell Reports 30, 2934–2947, March 3, 2020receptor agonists is sufficient to restore pulmonary defense in
microbiota-depleted (ABX) mice (Brown et al., 2017), our study
indicates that in IAV microbiota-colonized mice, supplementa-
tion with acetate is sufficient to restore host defense against
S. pneumoniae. However, we cannot exclude that in addition
to reduced SCFA (acetate), the dysbiotic IAV gut microbiota
might suppress antibacterial defense in the lungs via other
mechanisms yet to be unraveled. It is noteworthy that both
NOD-like receptor agonists (Brown et al., 2017) and acetate
(the present study) converge on enhanced macrophage effector
functions (bactericidal activity). Hence, the gut SCFA acetate
can target alveolar macrophages, a pathway affected during
IAV infection. It is likely that acetate directly targets alveolar
macrophages. Our recent data showed that IAV infection affects
monopoiesis in the bone marrow (Beshara et al., 2018), a phe-
nomenon not perturbed by exogenous acetate treatment (not
shown). Our results agree with a report demonstrating that gut
SCFAs can distally target macrophages (microglia, the brain’s
resident macrophages) to promote their innate effector functions
(Erny et al., 2015). They are also in agreement with Galv~ao and
collaborators, who showed that acetate protects against Klebsi-
ella pneumoniae (a Gram-negative bacterium) respiratory infec-
tion, an effect that depended on FFAR2 (Galv~ao et al., 2018).
Our findings are in line with the emerging concept whereby
gut SCFAs remotely influence immune responses in the lungs
and can modulate disease outcomes, including asthmatic reac-
tions (Cait et al., 2018; Maslowski et al., 2009; Trompette et al.,
2014) and respiratory viral and bacterial infections (Antunes
et al., 2019; Chakraborty et al., 2017; Galv~ao et al., 2018; Mor-
iyama and Ichinohe, 2019; Trompette et al., 2018). The SCFAs’
potential role in innate immune defenses against respiratory in-
fections has yet to be characterized in detail. Importantly, ace-
tate supplementation reduced, in a FFAR2-dependent manner,
the bacterial burden after the episode of influenza, despite the
immunosuppressive environment imposed by IAV. Of impor-
tance, this translated into reduced lung pathology and
improved survival rate of double-infected mice. Manipulation
of the gut microbiota (which, as we show, becomes deleterious
during influenza) might represent an interesting option to limit
post-influenza bacterial superinfections. Importantly, Tromp-
ette and collaborators have demonstrated that preventive sup-
plementation of diets enriched in fibers protected against influ-
enza infection (lower virus load and pathology) (Trompette
et al., 2018). This treatment is associated with enhanced fre-
quency of Bifidobacterium and Bacteroides genus and
enhanced levels of SCFAs (particularly butyrate). Remarkably,
butyrate controls influenza infection by reducing, through
enhanced CD8+ T cell activity, viral replication. This report is
fully in line with our current study, although the consequences
of high-fiber diets (or acetate-yielding diets) on secondary bac-
terial infections are presently unknown. Preventive consump-
tion of fermentable fibers, by protecting the SCFA-producing
compartment, may maintain intestinal homeostasis and rein-
force the lung’s defenses (against IAV and bacteria) during
influenza. In the same line, probiotics (e.g., SCFA producers
such as the Bifidobacteria and Lactobacillus spp) have been
successfully used in the context of IAV infection (Zelaya
et al., 2016), although their impact on superinfection was not
characterized. In the future, strategies that seek to harness the
power of the gut microbiota (via pre-/probiotics) to manage
influenza infections might help to control both viral diseases
and the harmful viral/bacterial synergy during bacterial superin-
fections. Alternatively, the use of SCFAs or FFAR2 agonists as
therapeutics might be envisaged to lower bacterial superinfec-
tion post-influenza. FFAR2 agonists are viewed as a promising
treatment of metabolic syndromes such as type 2 diabetes and
obesity (Milligan et al., 2017; Ulven, 2012). Our study shows the
positive effect of a synthetic FFAR2 agonist in respiratory infec-
tion and highlights a new opportunity for further development
against bacterial pneumonia.
The present study provided evidence that during influenza
infection, extrapulmonary disorders, namely dysbiosis, can
negatively influence bacterial superinfection. Further research
in this direction might help to define predictive markers (i.e., sys-
temic SCFAs) and/or develop therapeutic approaches against
these superinfections. Lastly, our findings might have broader
applications in the treatment of acute diseases associated with
an altered microbiota and secondary infections such as trauma,
burns, and sepsis.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice and ethics statement
Specific pathogen-free C57BL/6J mice (6 week-old, male) were purchased from Janvier (Le Genest-St-Isle, France). Mice were
maintained in a biosafety level 2 facility in the Animal ResourceCenter at the Lille Pasteur Institute for at least twoweeks prior to usageCell Reports 30, 2934–2947.e1–e6, March 3, 2020 e2
to allow appropriate acclimatation. All experiments complied with current national and institutional regulations and ethical guidelines
(Institut Pasteur de Lille/B59-350009 and CEEA 75. Nord Pas-de-Calais). All experiments were approved by the Ministe`re de l’Edu-
cation Nationale, de l’Enseignement Supe´rieur et de la Recherche, France (00357.03 and APAFIS 13743-2018022211144403).
Ffar2/ mice (> 10 backcrosses) were produced as previously described (Maslowski et al., 2009).
Viruses and bacteria
The mouse-adapted H3N2 IAV strain Scotland/20/1974, H1N1 IAV strain WSN/1933, H1N1 IAV strain California/04/2009 (pdm09),
and the clinical S. pneumoniae isolate E1586 (serotype 1) were described in Barthelemy et al. (2018).
METHOD DETAILS
Diets
Unless specified, mice were fed a standard rodent chow (SAFE A04) (SAFE, Augy, France) and water ad libitium. This diet contains
11.8% fiber including 10% water-insoluble fiber (3.6% cellulose) and 1.8% water-soluble fiber.
Infections and assessment of bacterial loads
For infection with IAV alone, mice were anesthetized by intramuscular injection of 1.25 mg of ketamine plus 0.25 mg of xylazine in
100 ml of phosphate buffered saline (PBS), and then intranasally (i.n.) infected with 50 ml of PBS containing (or not, in a mock sample)
30 plaque forming units (p.f.u.) of the H3N2 IAV strain A/Scotland/20/1974, 200 p.f.u. of the H1N1 IAV strain A/WSN/1933 or 100 p.f.u.
of H1N1 A/California/04/2009 (pdm09) (Barthelemy et al., 2017, 2018). These doses correspond to sub-lethal doses, which are
necessary to investigate secondary bacterial infection. For infection with S. pneumoniae alone, a high dose (1x106 c.f.u.) of
S. pneumoniae serotype 1, a serotype linked to invasive pneumococcal disease (clinical isolate E1586) was used. To deplete alveolar
macrophages, mice were i.n. inoculated with empty liposomes or clodronate liposomes (50ml, Liposoma, Amsterdam, the
Netherlands) 24 h before the S. pneumoniae challenge. For secondary pneumococcal infection, IAV (H1N1, pdm2009)-infected
mice were challenged at 7 dpi with a low dose (1x103 c.f.u.) of S. pneumoniae, a dose that is largely sufficient to allow bacterial
outgrowth and dissemination. In single and double infected mice, bacteria in the lungs and spleen were counted 30 h after the
S. pneumoniae challenge by plating serial 10-fold dilutions of lung or spleen homogenates onto blood agar plates. The plates
were incubated at 37Cwith 5%CO2 overnight and viable bacteria were counted 24 h later. Survival and bodyweightweremonitored
daily after IAV infection and mice were euthanized when they lost in excess of 20% of their initial body weight.
Reagents, antibodies, flow cytometry and cell sorting
The FFAR2 agonist TUG-1375 (2R,4R)-2-(2-chlorophenyl)-3-(4-(3,5-dimethylisoxazol-4-yl)benzoyl)thiazolidine-4-carboxylic acid)
and the FFAR3 agonist AR420626 (N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carbox-
amide were produced as described (Hansen et al., 2018; Hudson et al., 2014). Acetate, propionate and butyrate were from
Sigma-Aldrich (Saint Louis, MO). Ampicillin, neomycin, metronidazole, ciprofloxacinand and nystatin were from Sigma-Aldrich
and vancomycin was from R&D systems (Minneapolis, MN). Antibodies used for flow cytometry have been described in Barthelemy
et al. (2016, 2017). Flow cytometry analysis was performed exactly as described (Barthelemy et al., 2016). Monoclonal antibodies
against mouse CD45 (Brilliant Violet 510-conjugates), CD11b (PerCP-Cy5.5-conjugated), Siglec F (PE-conjugated), Ly6G
(APC-H7-conjugated), CD11c (PE-Cy7-conjugated), MHC class II (AF700-conjugated), CD64 (APC-conjugated), TCRb (PE-Cy7-
conjugated), TCRgd (PerCP-Cy5.5-conjugated), IFN-g (AlexaFluor-647), IL-17A (PE), and isotype controls were purchased from Bio-
Legend (San Diego, USA) and BD Bioscience (New Jersey, USA). PBS-57 glycolipid-loaded and unloaded control CD1d tetramers
(APC-conjugated) were from the National Institute of Allergy and Infectious Diseases Tetramer Facility (Emory University, Atlanta,
GA). The propidium iodide was purchased from BioLegend (San Diego, CA).
Cell immunostaining and flow cytometry were performed as previously described (Barthelemy et al., 2017). Briefly, mononuclear
cells from the lungs were plated in U-bottom 96-well plates and labeled for dead cells (ThermoFisher Scientific). To identify immune
cells, lung mononuclear cells were labeled with appropriate dilutions of conjugated antibodies exactly as described (Barthelemy
et al., 2017). The data were acquired on an LSRFortessa cytometer (Becton Dickinson Biosciences, Rungis, France) running FACS-
Diva software andwere then analyzed with FACSDiva software. For the analysis, 1x106 cells were acquired. Macrophageswere iden-
tified as CD45+ Siglec F+ CD11blow and neutrophils as CD45+ CD11b+ Ly6G+ Siglec F-. Conventional dendritic cells were identified as
CD45+ CD11c+high MHC class II+ Siglec F- CD64-, monocyte derived dendritic cells as CD45+ CD11c+ MHCII+ Cd11b+ Siglec F-
Ly6G- CD64+, gd T cells as CD45+ TCRb- TCRgd+ and invariant natural killer T as CD45+ TCRb+ CD1d tetramer+. Intracellular
FACS staining of iNKT cells and gd T cells was performed as described (Barthelemy et al., 2017; Hassane et al., 2017). After cell sur-
face labeling, alveolar macrophages were sorted using a FACSAria cytometer (BD Biosciences).
Sample collection, DNA extraction and 16S rRNA gene copy number
To study the impact of influenza infection on the gutmicrobiota, micewere i.n. infectedwith IAV and their feceswere collected at 7 dpi
and 14 dpi. Feces from each mouse were also sampled the day of infection (one hour before IAV infection) and served as controls.
Cecal samples were collected from different sets of animals including mock-treated mice and IAV-infected (7 dpi and 14 dpi) mice.e3 Cell Reports 30, 2934–2947.e1–e6, March 3, 2020
Fecal samples from vehicle-treated and acetate-treated mice were also collected at 7 dpi. Fecal and cecal samples as well as whole
cecum homogenates were stored at80Cuntil further analysis. Microbial DNAwas extracted from 150mg of fecal or cecal samples
(QIAamp DNA stool Kit, QIAGEN, Germany). The concentration of extracted DNA was determined using on a DNA fluorometric in-
tercalant (SYBR Green, ThermoFisher Scientific (Waltham, MA)). Bacterial loads were quantified using qPCR assays. Standard
curves were constructed to optimize the experiments and perform absolute quantification. The standard was a mix of 17 genomic
DNA extracted from different bacterial strains with an even 16S rRNA gene copy number of each strain. Briefly 4.8 ml (1 ng DNA) were
added into 10 ml of total volume mix (Taqman Universal MasterMix, Thermofischer) and optimized primer/probe concentrations to
obtain a 100 ± 10%qPCR efficiency on the standard and samples. Cycling condition were those recommended by themanufacturer.
Each sample was analyzed in triplicates. The Ct values were calculated using default parameters of software provided by the real-
time PCR instrument manufacturers (7900HT fast real-time PCR System, Thermofischer). Mean Ct values were finally confronted to
the standard curve to deduce the number of 16S rRNA gene copy in each sample.
16S rRNA gene pyrosequencing and data processing
The V3-V4 region of the 16S rRNA gene was amplified using an optimized and standardized amplicon-library preparation protocol
(Metabiote, GenoScreen, Lille, France). Positive (artificial bacteria Community comprising 17 different bacteria (ABCv2)) and nega-
tive (sterile water) control were also included. Briefly, PCR reactions were performed using 5ng of genomic DNA and in-house fusion
barcoded primers (at 0.2 mM final concentrations), with an annealing temperature of 50C for thirty cycles. PCR products were pu-
rified using Agencourt AMPure XP magnetic beads (Beckman Coulter, Brea, CA, USA), quantified according to GenoScreen’s pro-
tocol, andmixed in an equimolar amount. Sequencing was performed using 250-bp paired-end sequencing chemistry on the Illumina
MiSeq platform (Illumina, San Diego, CA, USA). Raw paired-end reads were then demultiplexed per sample and subjected to the
following process: (1) search and removal of both forward and reverse primer using CutAdapt, with no mismatches allowed in the
primers sequences; (2) quality-filtering using the PRINSEQ-lite PERL script, by truncating bases at the 30 end with Phred quality
score < 30; (3) paired-end read assembly using FLASH, with a minimum overlap of 30 bases and > 97% overlap identity.
Taxonomic Affiliation and diversity analyses
Taxonomic and diversity analyses were performed with the Metabiote Online v2.0 pipeline (GenoScreen, Lille, France) that is partially
based on the softwareQIIME v1.9.1. Following the pre-processing, the full-length 16S rRNA sequenceswere analyzed and chimeric se-
quences were removed from the dataset (in-house method based on the use of USEARCH8.1 algorithm). Then, a clustering step was
performed in order to group similar sequences with a nucleic identity defined threshold (97% identity for an affiliation at the genus level
on the V3-V4 regions of the 16S rRNA gene) with Uclust v1.2.22q through an open-reference operational taxonomic unit (OTU) picking
process and complete-linkagemethod, finally creating groupsof sequences orOTUs. AnOTUcleaning stepbasedon the dataobtained
for the ABCv2 community was performed. Themost abundant sequence of eachOTUwas considered as the reference sequence of its
OTU and was then taxonomically compared to a reference database (Greengenes database, release 13_8; https://greengenes.
secondgenome.com/) by the RDP classifier method v2.2. Various diversity indices were computed using QIIME v1.9.1. Alpha diversity
indices (within-sample) and beta diversity (between-sample) were used to examine changes inmicrobial community structure between
mice fecal and cecal group samples. Measurement of alpha diversity included Shannon diversity index, number of observed OTUs and
Chao1 index (richness and evenness). For b-diversity measures, we computed the weighted UniFrac distances. The principal coordi-
nates analysis (PCoA) method was used to visualize group overall microbial differences. Differences in relative abundance of individual
taxa, betweenmice cecal group samples, were assessed for significance using theMann-WhitneyU test controlling for false-discovery
rate (FDR), implemented within the software package QIIME. TheWilcoxon signed-rank test (paired t test) was used for 16S analysis of
fecal samples.
Measurement of food consumption and pair-feeding experiments
Food consumption was calculated daily during influenza infection. Briefly, a known amount of food was placed in a cage of six mice.
The amount of remaining food was measured every 12 h. The amount of consumed food was calculated by the difference divided by
six and expressed as food intake per mouse per day. To provide the pair-fed group with only as much food daily as is consumed by
IAV-infectedmice, we restricted the food access during the last three days for 15% (day 4), 35% (day 5) and 85% (day 6), respectively
(sacrifice at day 7). Mice were anesthetized at day 0. The pair-feeding time point was determined using data generated from IAV-in-
fectedmice with the goal of achieving a15% loss of bodymass (as at 7 dpi). Food was supplied twice a day to pair-fed animals and
water was available at all times. The ad libitum (normally nourished) group mice were allowed unrestricted access to food and water.
Weight loss of paired-fed mice and IAV-infected mice were measured in a daily manner. Fecal pellets (16S rRNA sequencing) and
cecal content (SCFA quantification) were collected at baseline (control) and seven days after (pair fed).
Measurement of SCFA concentrations and treatment with acetate or FFAR2/FFAR3 agonists
Concentrations of SCFAs in the cecal content were determined after extraction with diethyl ether using GC-2014 gas chromatog-
raphy with AOC-20i auto injector (Shimadzu, Hertogenbosch, the Netherlands) as described (DeWeirdt et al., 2010). Concentrations
of SCFAs in plasma were determined after extraction with acetonitrile. Results are expressed as mmol/g of cecal content or as mM
(blood). To assess the effects of SCFAs on lung defense against bacterial infection, conventional mice (no ABX treatment), miceCell Reports 30, 2934–2947.e1–e6, March 3, 2020 e4
recolonized with IAV microbiota and mice infected with IAV were treated with acetate (200 mM, drinking water) five days before the
S. pneumoniae challenge (1x106 c.f.u. for conventional and recolonized mice and 1x103 c.f.u. for IAV-infected mice, respectively).
IAV-infected mice were also treated (drinking water) with a combination of acetate, propionate and butyrate (200mM, 50mM and
5mM, respectively). The FFAR2 agonist TUG-1375 and the FFAR3 agonist AR420626 (stock solutions in DMSO at 20mM) were inoc-
ulated by the i.n. route (50 ml, 1 mM) 16 h before S. pneumoniae infection. Histopathological evaluation of the lung of double-infected
mice was performed as described previously (Horvat et al., 2007).
Quantification of viral loads and assessment of gene expression by quantitative RT-PCR
Total RNA from lung tissues were extracted with the NucleoSpin RNA kit (Macherey-Nagel, Hoerdt, Germany). RNA was reverse-
transcribed with the High-Capacity cDNAArchive Kit (Life Technologies, USA). The resulting cDNAwas amplified using SYBRGreen-
based real-time PCR and the QuantStudio 12K Flex Real-Time PCR Systems (Applied Biosystems, USA) following manufacturers
protocol. Relative quantification was performed using the gene coding glyceraldehyde 3-phosphate dehydrogenase (Gapdh). Spe-
cific primers were designed using Primer Express software (Applied Biosystems, Villebon-sur-Yvette, France) and ordered to Euro-
fins Scientifics (Ebersberg, Germany). Relative mRNA levels (2-DDCt) were determined by comparing (a) the PCR cycle thresholds (Ct)
for the gene of interest and the house keeping gene Gadph (DCt) and (b) DCt values for treated and control groups (DDCt). Data are
expressed as a fold-increase over the mean gene expression level in mock-treated mice. Quantification of viral RNA was performed
as described in Paget et al. (2011). Viral load is expressed as viral RNA normalized to gapdh expression level. Data were normalized
against expression of the gapdh gene and were expressed as Ct.
Microbiota transfer experiments
Mice received broad-spectrum ABXs (ampicillin 2g/L; neomycin 2g/L, metronidazole 1g/l, ciprofloxacin 1g/l, nystatin 0.08 g/L and
vancomycin 0.5g/l) in drinking water supplemented with glucose (10 g/l) for three weeks. The cages were changed every two
days. Depletion of bacteria in the feces were checked after culture in thioglycollate broth medium (Sigma) for 24 h at 37C. ABX-
treated mice were colonized twice (three days and five days after ABX cessation) by oral administration of 200 ml of cecal suspension
containing 1x109 bacteria recovered from naive mice, mock-treated mice or IAV-infected mice (7 dpi). Colonized mice were infected
with S. pneumoniae (1x106 c.f.u.) three days after the first colonization. Weights of control and ABX-treated mice (colonized or not)
were equal at the moment of pneumococcal inoculation.
In vivo phagocytosis and killing assays and assessment of pneumococcal load in alveolar macrophages
To visualize bacteria associated with phagocytes or internalized by phagocytes, recolonized mice were infected with eGFP-express-
ing S. pneumoniae (1x106 c.f.u., serotype 1) (a gift from Dr JW Veening, university of Groningen, the Netherlands). Four hours later,
BAL fluid cells (> 95% alveolar macrophages) were washed and plated (u-Slide 8 Well ibiTreat, IBIDI, Martinsried, Germany). Mem-
branes were labeled (CellMaskDeep red plasmamembrane stain, Thermofisher) and after washes and fixation, nucleus were labeled
with DAPI (Thermofisher) and maintained in PBS. Samples were observed with CLSM Zeiss LSM 880 (Zeiss, Oberkochen, Germany)
with Plan Apochromat 63xoil/1.4 objective. Excitation was performed with an Argon laser (458 to 488 to 514 nm) or a laser diode
(561 nm and 405nm) (Lasos Lasertechnik GmbH, Jena, Germany). The spectral detection range was adjusted for each fluorophore
by using aQuasar detection unit. Images were acquiredwith ZEN software (Zeiss, Carl Zeiss, Oberkochen, Germany), deconvoled by
AutoQuant software (Bitplane, Oxford Instruments company, Zurich, Switzerland) and assembled using ImageJ software. The fre-
quency of macrophages having internalized S. pneumoniae and the average number of internalized bacteria per macrophage
were determined (more than 20 visual fields analyzed/mouse). To determine the pneumococcal load in alveolar macrophages, cells
(CD45+ Siglec Fhi CD11b-) were sorted using a FACSAria cytometer (BD Biosciences) (> 99% purity). DNA was extracted and
analyzed using quantitative PCR (QuantStudio 12K Flex, Applied Biosystems). Data were normalized against expression of the gapdh
gene andwere expressed asDCt. To determine the bactericidal activity of macrophages, re-colonizedmicewere infectedwith 1x 106
c.f.u. of S. pneumoniae (serotype 1). Four hours later, BAL fluid cells were collected and extensively washedwith PBS in the presence
of 15 mg/ml of gentamycin (Thermo Fisher Scientific). Cells were then washed twice in sterile PBS and lysed in sterile double de-
ionized water. To assess bacterial killing, the number of ingested viable bacteria was determined by quantitative plating of serial di-
lutions of the lysates onto blood agar plates. The number of viable bacteria was expressed per 1x105 cells.
In vitro killing assay
For the in vitro killing assay, macrophages were pre-treated with acetate (10mM) for 1 h and then exposed with opsonized
S. pneumoniae at MOI 10. Cells were incubated at 4C for 1 h, followed by 3h of incubation at 37C for bacterial internalization. Cells
were washed in sterile PBS, incubated with penicillin and streptomycin (30U/ml) for 30min to kill extracelllular bacteria and then
washed and incubated with vancomycin (0.75mg/ml) for 2 h. Bacterial-exposed macrophages were lysed at 0 and 2 h post exposure.
The number of viable bacteria were determined by quantitative plating of serial dilutions of the lysates onto blood agar plates.e5 Cell Reports 30, 2934–2947.e1–e6, March 3, 2020
S. pneumoniae outgrowth in vitro
S. pneumoniae colonies at exponential growth were added to Todd Hewitt Broth at the absorbance of 0.04 OD (600 nm) in the
absence or presence of 0.1, 1 or 10mM of acetate, or 1U/ml of pennicilin and 1 mg/ml streptomycin used here as a positive control.
The O.D. was measured every 30 minutes.
QUANTIFICATION AND STATISTICAL ANALYSIS
Results are expressed as the mean ± standard deviation (SD) unless otherwise stated. All statistical analysis was performed using
GraphPad Prism v6 software. A Mann-Whitney U test was used to compare two groups unless otherwise stated. The Wilcoxon
signed-rank test (paired t test) was used for 16S analysis of fecal samples. Comparisons of more than two groups with each other
were analyzed with the One-way ANOVA Kruskal-Wallis test (nonparametric), followed by the Dunn’s posttest. Survival of mice was
compared using Kaplan-Meier analysis and log-rank test.*, p < 0.05; **, p < 0.01; ***, p < 0.001. Statistical details of experiments can
be found in the figure legends. Sample sizes were dictated to adhere to the French home office 3R principles, while providing appro-
priate statistical power.
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